scholarly journals A hepatic sclerosing hemangioma emerged in the postoperative course of multiple gastric carcinoid tumors masquerading as metachronous liver metastasis

2019 ◽  
Vol 58 ◽  
pp. 1-5
Author(s):  
Ryota Koyama ◽  
Nozomi Minagawa ◽  
Yoshiaki Maeda ◽  
Toshiki Shinohara ◽  
Tomonori Hamada
2001 ◽  
Vol 120 (5) ◽  
pp. A298-A299
Author(s):  
A SAFATLERIBEIRO ◽  
U RIBEIRO ◽  
C KOBATA ◽  
C CORBETT ◽  
K IRIYA ◽  
...  

2019 ◽  
Vol 6 (2) ◽  
pp. 125-126
Author(s):  
Mustapha Benamer ◽  
◽  
Radia Satha ◽  
Fifi Otmani

La maladie de Biermer (MB) est une entité auto-immune. Elle est causée par un déficit en facteur intrinsèque, secrété par les cellules pariétales gastriques, secondaire à une atrophie fundique, entrainant une diminution de la sécrétion de l’ion H+ et une malabsorption iléale de la vitamine B12. La MB se caractérise sur le plan clinique par un syndrome neuro-anémique et la tumeur carcinoïde (TC) peut être une de ses complications survenant au cours du processus évolutif. Cette observation soulève la rareté de l’association, propose la compréhension des mécanismes physiopathologiques et discute les thérapies actuelles.


2020 ◽  
Vol 35 (12) ◽  
pp. 2205-2217
Author(s):  
Zhou Jiaming ◽  
Huang Pinzhu ◽  
Guo Xiaoyan ◽  
Tan Shuyun ◽  
Lin Rongwan ◽  
...  

2019 ◽  
Vol 26 (11) ◽  
pp. 1495-1504 ◽  
Author(s):  
Meng Liang ◽  
Zhengting Cai ◽  
Hongmei Zhang ◽  
Chencui Huang ◽  
Yankai Meng ◽  
...  

2007 ◽  
Vol 292 (4) ◽  
pp. G1133-G1140 ◽  
Author(s):  
Andrea Varro ◽  
Susan Kenny ◽  
Elaine Hemers ◽  
Catherine McCaig ◽  
Sabine Przemeck ◽  
...  

Chronic hypergastrinemia is associated with enterochromaffin-like (ECL) cell hyperplasia, which may progress to gastric carcinoid tumors. The latter consists of epithelial cells and stroma, and both compartments usually regress after normalization of hypergastrinemia. We previously showed that matrix metalloproteinase (MMP)-7 in gastric epithelial cells was upregulated by Heliobacter pylori and described MMP-7-dependent reciprocal signaling between the epithelium and a key stromal cell type, the myofibroblast. Here, we describe the regulation of gastric MMP-7 by gastrin and the potential significance for recruiting and maintaining myofibroblast populations. Biopsies of the gastric corpus and ECL cell carcinoid tumors were obtained from hypergastrinemic patients. Western blot analysis, ELISA, immunohistochemistry, and promoter-luciferase (luc) reporter assays were used to study MMP-7 expression. Gastric myofibroblasts were identified by α-smooth muscle actin (α-SMA) expression, and the effects of MMP-7 on myofibroblast proliferation were investigated. In hypergastrinemic patients, there was an increased abundance of MMP-7 and α-SMA in gastric corpus biopsies and ECL cell carcinoid tumors. In the latter, MMP-7 was localized to ECL cells but not stromal cells, which were nevertheless well represented. Gastrin stimulated MMP-7-luc expression in both AGS-GR and primary human gastric epithelial cells. Conditioned medium from gastrin-treated human gastric glands stimulated myofibroblast proliferation, which was inhibited by neutralizing antibodies to MMP-7. MMP-7 increased the proliferation of myofibroblasts via the MAPK and phosphatidylinositol 3-kinase (PI3K) pathways. In conclusion, stimulation of gastric MMP-7 by elevated plasma gastrin may activate epithelial-mesenchymal signaling pathways regulating myofibroblast function via MAPK and PI3K pathways and contribute to stromal deposition in ECL cell carcinoid tumors.


2008 ◽  
Vol 13 (5) ◽  
pp. 179-188
Author(s):  
Susan C. Abraham

2010 ◽  
Vol 162 (1) ◽  
pp. 22-25 ◽  
Author(s):  
Junko Ozao-Choy ◽  
Kerri Buch ◽  
James A. Strauchen ◽  
Richard R.P. Warner ◽  
Celia M. Divino

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 511-511
Author(s):  
Jianmin Xu ◽  
Jianguo Xia ◽  
Yan Gu ◽  
Jianjiang Lin ◽  
Kefeng Ding ◽  
...  

511 Background: To evaluate the addition of preoperative hepatic and regional arterial chemotherapy (PHRAC) on prognosis for stage II and III colorectal cancer in a multicenter setting. Methods: Patients with clinical stage II or stage III colorectal cancer (CRC) were randomly assigned to receive PHRAC plus adjuvant therapy (PHRAC arm) or adjuvant therapy alone (control arm). The primary end point was disease free survival (DFS). Second end points were incidence of metachronous liver metastasis, overall survival (OS) and safety. Results: A total of 688 patients from 5 centers of China were randomly assigned to each arm. Five-year DFS were 75% for PHRAC arm and 61% for control arm (HR 0.60; 95% CI, 0.45 to 0.80; p<0.001). Five-year liver-metastasis rate was 8% and 18% in PHRAC arm and control arm, respectively (HR 0.39; 95% CI, 0.24 to 0.64; p<0.001). Five-year OS was 81% in PHRAC arm and 72% in control arm (HR 0.59; 95% CI, 0.42 to 0.84; p=0.003). There were no significant differences in morbidity or mortality between two arms. The results of eligible patients were barely changed. Subgroup analysis shows differences of DFS, liver-metastasis rate and OS were significant in stage III patients, but not in stage II patients. Conclusions: Additional PHRAC could reduce the incidence of metachronous liver metastasis and improve DFS and OS in patients with stage III CRC, without compromising patient safety. Clinical trial information: NCT00643877.


Sign in / Sign up

Export Citation Format

Share Document